Parade Technologies Offers Best-in-class latency for CXL Retimer Solutions

1 year ago

Parade’s PS8936 offers latencies that are only a fraction of those of the competition SAN JOSE, Calif.--(BUSINESS WIRE)--Parade Technologies, Ltd.…

AI Singapore Awards S$20M in Research Funds to Address Challenges Relating to Increase Use of AI in Emerging Apps

1 year ago

Research outcomes have potential for dual-use applications, for leverage by both the industry & defence SINGAPORE - Media OutReach -…

Nut Techy Launches “Computing Power Investment” to Boost Business Market Value and User Base

1 year ago

SINGAPORE - Media OutReach - 26 July 2023 - Recently, well-known computing power operator Nut Techy launched a new business…

LogicMonitor Expands Relationship With AWS

1 year ago

More monitoring coverage across services and enhanced capabilities with AWS leads to cost savings, better uptime and improved visibility into…

Recent Cash Injection Boosts VectorBuilder to Unicorn Status

1 year ago

CHICAGO--(BUSINESS WIRE)--Gene delivery technologies are turning into the next big-ticket item globally, as the most recent investment received by VectorBuilder…

Endace Scalable Packet Capture Delivers Unified Visibility Across Hybrid Cloud

1 year ago

EndaceProbe Cloud provides scalable packet capture for unified visibility across on-premise, private-cloud and public cloud environments AUCKLAND, New Zealand &…

Nickel 28 Releases Ramu Q2 2023 Operating Performance

1 year ago

TORONTO--(BUSINESS WIRE)--$NKL #mining--Nickel 28 Capital Corp. (“Nickel 28” or the “Company”) (TSXV: NKL) (FSE: 3JC0) is pleased to provide operational…

Identiv Starts Production at New Facility in Bangkok, Thailand

1 year ago

New Production Facility Meets Growing Demand for IoT Solutions FREMONT, Calif.--(BUSINESS WIRE)--Identiv, Inc. (Nasdaq: INVE), a global digital security and…

Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma

1 year ago

V940-001 is the first Phase 3 study of a planned comprehensive clinical development program being initiated following the positive primary…

UMC Reports Second Quarter 2023 Results

1 year ago

Company’s differentiating specialty technologies accounted for 59% of Q2 revenue Solid 22/28nm business momentum lifted contribution to 29% Second Quarter…